BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single ins
- PDF / 1,544,969 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 53 Downloads / 147 Views
HEAD AND NECK
BRAF V600E mutation‑specific immunohistochemical analysis in ameloblastomas: a 44‑patient cohort study from a single institution Adepitan A. Owosho1 · Adeola M. Ladeji2 · Kehinde E. Adebiyi2 · Mofoluwaso A. Olajide2 · Ikechukwu S. I. Okoye2 · Temitope Kehinde3 · Ngozi N. Nwizu4 · Kurt F. Summersgill5 Received: 20 August 2020 / Accepted: 10 November 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose The aim of this study is to investigate the presence and prevalence of BRAF V600E mutation in ameloblastomas using anti-BRAF V600E monoclonal antibody (VE1 clone) and to identify any clinicopathologic correlation with BRAF V600E mutation in ameloblastoma. Materials and methods The pathology files of the Department of Oral Pathology and Oral Medicine, Faculty of Dentistry, Lagos State University College of Medicine, Lagos, Nigeria, were searched for the diagnosis of ameloblastoma from 2016 to 2020. Archived non-decalcified formalin-fixed paraffin-embedded tissue underwent immunohistochemistry using antiBRAF V600E antibody at the University of Pittsburgh, Pennsylvania. Clinicopathologic data such as age at diagnosis, gender, jaw bone involved (mandible or maxilla), tumor location (anterior or posterior) and histologic subtype were collected. The clinicopathologic parameters were analyzed using Chi-square test and Fisher’s exact test according to the BRAF status. Results Forty-four cases of ameloblastoma were retrieved. The male to female ratio was 1.32:1. The average age of patients at diagnosis was 33.3 years. Thirty-nine cases were located in the mandible and 5 cases in the maxilla. Only cases in the mandible were positive for anti-BRAF V600E antibody (n = 15/39; 38.5%). There was a significant correlation between BRAF V600E expression in mandibular tumors and histologic subtype (p = 0.02); however, no significance was observed for gender, age and tumor location. Conclusion BRAF V600E mutation preferentially occurs in mandibular ameloblastomas, especially in non-plexiform ameloblastomas. These patients may benefit therapeutically from the use of BRAF inhibitors. Keywords Odontogenic tumor · Ameloblastoma · BRAF · Jaw tumors · Mutation
Introduction Adepitan A. Owosho and Adeola M. Ladeji contributed equally to this work. * Adepitan A. Owosho [email protected] 1
Missouri School of Dentistry and Oral Health, A.T. Still University, 800 W Jefferson Street, Kirksville, MO, USA
2
Department of Oral Pathology and Oral Medicine, Faculty of Dentistry, Lagos State University College of Medicine, Lagos, Nigeria
3
Department of Pathology, Anatomy and Laboratory Medicine, West Virginia University, Morgantown, WV, USA
4
Department of Diagnostic and Biomedical Science, School of Dentistry, The University of Texas, Health Science Center at Houston, Houston, TX, USA
5
Department of Diagnostic Sciences, School of Dental Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Odontogenic tumors are a heterogeneous group of tumors that arise from remnants of
Data Loading...
